VivoSeq
Infectious Disease

Genital Herpes

23

Pipeline Programs↗

3

Active Trials↗

12

Companies Involved↗

Genital Herpes is an emerging landscape with 23 programs across 12 companies. The most active players are Assembly Biosciences, BioNTech, Resolve Therapeutics. 3 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

48/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

79/100

Attrition Rate

19/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Assembly Biosciences

2 programs

Phase 1BioNTech logo

BioNTech

1 program

Phase 1R

Resolve Therapeutics

1 program

Phase 1G

Genocea Biosciences, Inc.

2 programs

Phase 2Astellas logo

Astellas

1 program

Phase 2Moderna logo

Moderna

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

89%

Small molecule

16 of 18 classified programs — the dominant modality here.

11%ALL OTHERSRNA therapy16%Vaccine16%

Small molecule leads; the ring shows all 18 classified programs, each share of the total. Modality classified for 100% of 32 pipeline programs.

Analysis

Trial Status

32

clinical trials

Completed22 · 69%
Terminated6 · 19%
Active, not recruiting2 · 6%
Unknown status1 · 3%
Not yet recruiting1 · 3%

Clinical Trials

Trial Activity

32 trials

A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-5366 in Healthy Participants and Participants Seropositive for HSV-2 With Recurrent Genital Herpes
Active, not recruiting·AAssembly Biosciences·Phase 1·NCT06385327·115 enrolled
A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions
Active, not recruiting·BioNTech logoBioNTech·Phase 1·NCT05432583·318 enrolled
Evaluating Safety and Efficacy of Repeat Doses of UB-621in Adult Patients With Recurrent Genital Herpes
Not yet recruiting·UUBP Greater China (Shanghai) Co., Ltd·Phase 2·NCT04979975·200 enrolled
Melatonin Effects on Genital Herpes in Brazilian Women
Completed·UUniversity of Sao Paulo General Hospital·Phase 4·NCT03831165·90 enrolled
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
Completed·Astellas logoAstellas·Phase 2·NCT00486200·695 enrolled
Safety of a Herpes Simplex Candidate Vaccine (gD2t) With MPL and Its Efficacy to Prevent Genital Herpes Disease
Completed·GSK logoGSK·Phase 3·NCT00699764·2,491 enrolled
Safety and Efficacy Study for a New Antiviral Drug to Treat Genital Herpes Type 2
Completed·AAiCuris Anti-infective Cures AG·Phase 2·NCT01047540·156 enrolled
A Comparative Trial of Valacyclovir Hydrochloride ( 256U87 ) and Acyclovir for the Suppression of Anogenital Herpes Infections in HIV-Infected Patients
Completed·GSK logoGSK·N/A·NCT00002084
Randomised Controlled Trial Assessing the Impact of Genital Herpes Suppressive Therapy on HIV Shedding
Completed·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 2·NCT00158509·215 enrolled
Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes
Completed·Novartis logoNovartis·Phase 3·NCT00306787·1,179 enrolled
A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes
Completed·AAssembly Biosciences·Phase 1·NCT06698575·103 enrolled
Patient-initiated Episodic Treatment of Recurrent Genital Herpes in Black Patients
Completed·Novartis logoNovartis·Phase 4·NCT00477334·463 enrolled
Effect of Tenofovir on Genital Herpes Simplex Virus (HSV) Shedding
Completed·UUniversity of Washington·Phase 4·NCT01448616·73 enrolled
A Study to Compare the Efficacy and Safety of Valacyclovir Hydrochloride ( 256U87 ) Versus Acyclovir in the Treatment of Recurrent Anogenital Herpes Infections in HIV Infected Patients
Completed·GSK logoGSK·N/A·NCT00002000
Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital Herpes
Completed·AAgenus Inc.·Phase 2·NCT01687595·80 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)